Navigation Links
GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Date:1/15/2008

tigen in the GelVac(TM) formulation has been stable at ambient room temperature for 36 months.

The nasal cavity is increasingly recognized as the ideal immunization route since most infectious diseases enter the body through mucosal surfaces such as those found in the nasal cavity, the lungs, and the intestines. Nasal immunization not only induces a systemic response, but also induces mucosal response, providing protection at the entry point. GelVac(TM) is a novel in- situ gelling powder formulation for nasal delivery. The GelSite(R) polymer enables in-situ gelling of the vaccine powder, which changes into gel particles upon exposure to nasal fluids present in the nasal passage. This gel adheres to the mucosal lining and provides prolonged residence time and sustained antigen release that, in turn, increase antigen delivery.

About DelSite

Carrington's wholly owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.

A Drug Master File (DMF) has been filed with the FDA for GelSite(R) polymer which may be made in kilogram quantities under cGMP guidelines in an ISO-certified facility.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Ca
'/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
4. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
7. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
8. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. Vical Presentation at Military Pandemic Influenza Workshop
11. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... - FDA Targets January 11, 2008 as Action Date, ... SPPI ) today announced that the amendment to,the ... LFA),for injection has been accepted by the U.S. Food ... 2008 as its action date regarding,the approval of the ...
... Asset Exchange Agreement, COPENHAGEN, September 13 ... an asset exchange agreement with,Medarex, Inc. Under the ... to HuMax-Inflam(TM)/MDX-018, which targets IL-8, and Medarex will,receive ... Genmab and,Medarex will release to each other all ...
... UPTON, NY Scientists at the U.S. Department of ... for controlling the self-assembly of nanometer and micrometer-sized particles. ... a particles surface, can be used to manipulate the ... of numerous materials that may be of interest ...
Cached Biology Technology:FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals 2FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals 3Genmab Announces Asset Exchange Agreement 2New DNA-based technique for assembly of nano- and micro-sized particles 2
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... say they have discovered a cause-and-effect relationship between ... believed to be independent of one another. ... better drugs to treat the cognitive dysfunction associated ... ,Researchers have long studied the role played in ...
... Rice University and Lockheed Martin reported this month that ... from a single silicon wafer. The process uses simple ... lithium-ion batteries, laying the groundwork for longer-lasting, more powerful ... vehicles. The work led by Sibani Lisa Biswal, ...
... up their arms, clench their fists and grimace after a ... the same across cultures, a new study suggests. New findings ... Human Behavior suggest this victory pose signals feelings of ... "We found that displays of triumph include different behaviors ...
Cached Biology News:Johns Hopkins researchers link 2 biological risk factors for schizophrenia 2Toughened silicon sponges may make tenacious batteries 2Victory stance may be a universal gesture of triumph -- not pride -- study suggests 2
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
... modular, computer controlled pre-amplifier suitable for a ... electrode input for recording physiological signal such ... a transducer input for use with a ... Additional options include a stimulus artefact clamp ...
SYBR Green Nucleic Acid Dye...
... 384 cap mat made from an inert ... Features 384 split septum caps ... AB-1056) Suitable for PCR when used in ... cyclers Pierceable with standard pipetting equipment ...
Biology Products: